Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/67536
Type
ArticleCopyright
Open access
Sustainable Development Goals
03 Saúde e Bem-Estar05 Igualdade de gênero
10 Redução das desigualdades
17 Parcerias e meios de implementação
Collections
- INI - Artigos de Periódicos [3646]
- IOC - Artigos de Periódicos [12969]
Metadata
Show full item record
IMPACT OF COVID-19 PANDEMIC ON HIV TESTING, RECENT INFECTIONS, AND ANNUALIZED INCIDENCE AMONG CISGENDER MEN WHO HAVE SEX WITH MEN AND TRANSGENDER WOMEN IN BRAZIL
HIV incidence
COVID-19
Men who have sex with men
Transgender women
Sexual and gender minorities
https://www.arca.fiocruz.br/handle/icict/66071
Supplemental Digital Content: this article contains supplemental content that can be downloaded by clicking a link in the full text: https://links.lww.com/QAI/C366
Author
Jalil, Cristina Moreira
Teixeira, Sylvia Lopes Maia
Coutinho, Carolina Fausto de Souza
Costa, Sandro Coutinho Nazer da
Carvalheira Netto, Eduardo
Hoagland, Brenda Regina de Siqueira
Cardoso, Sandra Wagner
Luz, Paula Mendes
Veloso, Valdiléa G.
Grinsztejn, Beatriz
Jalil, Emilia Moreira
Torres, Thiago Silva
Teixeira, Sylvia Lopes Maia
Coutinho, Carolina Fausto de Souza
Costa, Sandro Coutinho Nazer da
Carvalheira Netto, Eduardo
Hoagland, Brenda Regina de Siqueira
Cardoso, Sandra Wagner
Luz, Paula Mendes
Veloso, Valdiléa G.
Grinsztejn, Beatriz
Jalil, Emilia Moreira
Torres, Thiago Silva
Affilliation
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Aids e Imunologia Molecular. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Aids e Imunologia Molecular. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Abstract
Background: The COVID-19 pandemic had great impact on HIV care and prevention worldwide, including in Brazil. We compared HIV testing, recent infection, and annualized incidence according to the COVID-19 pandemic period among cisgender men who have sex with men (MSM) and transgender women (TGW). Setting: HIV and sexually transmitted infection testing, prevention, and treatment referral service in Rio de Janeiro, Brazil. Methods: We used Maxim HIV-1 Limiting Antigen Avidity EIA as part of a recent infection testing algorithm to identify recent HIV infection cases and estimate annualized HIV incidences in the pre- (March 2018–February 2020) and post-COVID-19 pandemic onset period (March 2020–January 2022). Multivariable logistic regression model assessed factors associated with recent HIV infection. Results: Among 3814 MSM and 776 TGW, 593 (12.9%) tested positive for HIV and 119 (2.6%) were identified as having recent infection. Percentage of recent HIV infection did not differ between the COVID-19 periods. Overall annualized HIV incidence rates were 6.0% (95% confidence interval [CI]: 4.2 to 7.7) and 6.6% (95% CI: 4.3 to 9.0) in the pre- and post-COVID-19 periods, respectively. During the post-COVID-19 period, higher incidence rates were observed among TGW (8.4% [95% CI: 2.9 to 13.9]), those aged 18–24 years (7.8% [95% CI: 4.0 to 11.7]), of Black race (7.9% [95% CI: 3.8 to 12.0]), and those with <12 years of schooling (7.8% [95% CI: 4.8 to 10.8]). Compared to the pre-COVID-19 period, incidence rates were significantly higher in the post-COVID-19 period for those aged >30 years and TGW, while being lower for those with more years of schooling. Conclusion: HIV incidence estimates remain high among MSM and TGW in Brazil, especially among the most vulnerable. The consequences of the COVID-19 pandemic on the HIV epidemic will likely persist and contribute to worsening HIV outcomes.
Keywords
Recent HIV infectionHIV incidence
COVID-19
Men who have sex with men
Transgender women
Sexual and gender minorities
Publisher
Lippincott, Williams & Wilkins
Citation
JALIL, Cristina Moreira et al. Impact of COVID-19 pandemic on HIV testing, recent infections, and annualized incidence among cisgender men who have sex with men and transgender women in Brazil. Journal of Acquired Immune Deficiency Syndrome, v. 98, n. 1, p. 12-19, 1 Jan. 2025.Previous version
DOI
10.1097/QAI.0000000000003531ISSN
1525-4135Notes
Produção científica do Laboratório de Aids e Imunologia Molecular.Supplemental Digital Content: this article contains supplemental content that can be downloaded by clicking a link in the full text: https://links.lww.com/QAI/C366
Share